These researchers concluded “that targeting cytokines, cytokine receptors, and inflammation-associated nuclear transcription factors, such as IL-1β, IL-αR, TNF-α, and NF-kB alone or in combination, can significantly reduce the level of FPG, HbA1c, and CRP in patients with type-2 diabetes. The gene discussed is CRP; the disease is type 2 diabetes mellitus.